A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs

Overview

Journal Front Bioinform

Specialty Biology

Date 2022 Oct 28

PMID 36303796

Authors

Georgi I Kapitanov

Jeffrey R Chabot

Jatin Narula

Mahua Roy

Hendrik Neubert

Joe Palandra

Vahid Farrokhi

Jay S Johnson

Robert Webster

Hannah M Jones

Affiliations

Soon will be listed here.

Abstract

Quantitative modeling is increasingly utilized in the drug discovery and development process, from the initial stages of target selection, through clinical studies. The modeling can provide guidance on three major questions-is this the right target, what are the right compound properties, and what is the right dose for moving the best possible candidate forward. In this manuscript, we present a site-of-action modeling framework which we apply to monoclonal antibodies against soluble targets. We give a comprehensive overview of how we construct the model and how we parametrize it and include several examples of how to apply this framework for answering the questions postulated above. The utilities and limitations of this approach are discussed.

Citing Articles

Editorial: Model-informed decision making in the preclinical stages of pharmaceutical research and development.

Li R, Craig M, DArgenio D, Betts A, Mager D, Maurer T Front Pharmacol. 2023; 14:1184914.

PMID: 37124233 PMC: 10131111. DOI: 10.3389/fphar.2023.1184914.

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions.

Grant J, Hua F, Apgar J, Burke J, Marcantonio D MAbs. 2023; 15(1):2192251.

PMID: 36951503 PMC: 10038042. DOI: 10.1080/19420862.2023.2192251.

Modulating Immune Response in Viral Infection for Quantitative Forecasts of Drug Efficacy.

Costa B, Vale N Pharmaceutics. 2023; 15(1).

PMID: 36678799 PMC: 9867121. DOI: 10.3390/pharmaceutics15010167.

Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions.

Marcantonio D, Matteson A, Presler M, Burke J, Hagen D, Hua F Front Pharmacol. 2022; 13:864768.

PMID: 35754500 PMC: 9214263. DOI: 10.3389/fphar.2022.864768.

References

May R, Fung M . Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015; 75(1):89-116. DOI: 10.1016/j.cyto.2015.05.018. View

Palmer G, Lipsky B, Smithgall M, Meininger D, Siu S, Talabot-Ayer D . The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008; 42(3):358-64. DOI: 10.1016/j.cyto.2008.03.008. View

Danhof M, Klein K, Stolk P, Aitken M, Leufkens H . The future of drug development: the paradigm shift towards systems therapeutics. Drug Discov Today. 2018; 23(12):1990-1995. DOI: 10.1016/j.drudis.2018.09.002. View

Shah D, Betts A . Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2011; 39(1):67-86. DOI: 10.1007/s10928-011-9232-2. View

Nestorov I . Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 2007; 3(2):235-49. DOI: 10.1517/17425255.3.2.235. View

Grimm H . Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn. 2009; 36(5):407-20. DOI: 10.1007/s10928-009-9129-5. View

An B, Zhang M, Pu J, Qu Y, Shen S, Zhou S . Toward Accurate and Robust Liquid Chromatography-Mass Spectrometry-Based Quantification of Antibody Biotherapeutics in Tissues. Anal Chem. 2020; 92(22):15152-15161. DOI: 10.1021/acs.analchem.0c03620. View

Popovic B, Breed J, Rees D, Gardener M, Vinall L, Kemp B . Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2016; 429(2):208-219. DOI: 10.1016/j.jmb.2016.12.005. View

Peterson M, Riggs M . FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?. CPT Pharmacometrics Syst Pharmacol. 2015; 4(3):e00020. PMC: 4394612. DOI: 10.1002/psp4.20. View

10.

Khodoun M, Lewis C, Lewis C, Yang J, Orekov T, Potter C . Differences in expression, affinity, and function of soluble (s)IL-4Ralpha and sIL-13Ralpha2 suggest opposite effects on allergic responses. J Immunol. 2007; 179(10):6429-38. DOI: 10.4049/jimmunol.179.10.6429. View

11.

Saluja R, Zoltowska A, Ketelaar M, Nilsson G . IL-33 and Thymic Stromal Lymphopoietin in mast cell functions. Eur J Pharmacol. 2015; 778:68-76. DOI: 10.1016/j.ejphar.2015.04.047. View

12.

Bateman R, Munsell L, Morris J, Swarm R, Yarasheski K, Holtzman D . Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12(7):856-61. PMC: 2983090. DOI: 10.1038/nm1438. View

13.

Gluck J, Rymarczyk B, Jura-Szoltys E, Rogala B . Serum levels of interleukin 33 and its receptor ST2 in patients treated with subcutaneous allergen immunotherapy in intermittent allergic rhinitis. Cent Eur J Immunol. 2019; 44(2):214-217. PMC: 6745539. DOI: 10.5114/ceji.2019.87075. View

14.

Schutyser E, Struyf S, Van Damme J . The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003; 14(5):409-26. DOI: 10.1016/s1359-6101(03)00049-2. View

15.

Shuford C, Johnson J, Thompson J, Holland P, Hoofnagle A, Grant R . More sensitivity is always better: Measuring sub-clinical levels of serum thyroglobulin on a µLC-MS/MS system. Clin Mass Spectrom. 2021; 15:29-35. PMC: 8601006. DOI: 10.1016/j.clinms.2020.01.001. View

16.

Owen S, Francis H, Roberts M . Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol. 1994; 38(4):349-55. PMC: 1364779. DOI: 10.1111/j.1365-2125.1994.tb04365.x. View

17.

Grass G, Sinko P . Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev. 2002; 54(3):433-51. DOI: 10.1016/s0169-409x(02)00013-3. View

18.

Liu Y, Cao L, Chen R, Zhou X, Fan X, Liang Y . Osteopontin Promotes Hepatic Progenitor Cell Expansion and Tumorigenicity via Activation of β-Catenin in Mice. Stem Cells. 2015; 33(12):3569-80. DOI: 10.1002/stem.2072. View

19.

De Boever E, Ashman C, Cahn A, Locantore N, Overend P, Pouliquen I . Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014; 133(4):989-96. DOI: 10.1016/j.jaci.2014.01.002. View

20.

Ashkar S, Weber G, Panoutsakopoulou V, Sanchirico M, Jansson M, Zawaideh S . Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287(5454):860-4. DOI: 10.1126/science.287.5454.860. View